Last €14.88 EUR
Change Today -0.055 / -0.37%
Volume 7.5K
As of 2:16 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

astellas pharma inc (YPH) Snapshot

Open
€14.97
Previous Close
€14.93
Day High
€14.99
Day Low
€14.88
52 Week High
03/4/15 - €15.11
52 Week Low
04/14/14 - €7.61
Market Cap
33.6B
Average Volume 10 Days
1.8K
EPS TTM
--
Shares Outstanding
2.3B
EX-Date
03/27/15
P/E TM
--
Dividend
€29.45
Dividend Yield
1.35%
Current Stock Chart for ASTELLAS PHARMA INC (YPH)

Related News

No related news articles were found.

astellas pharma inc (YPH) Related Businessweek News

View More BusinessWeek News

astellas pharma inc (YPH) Details

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on the therapeutic areas of urology, immunology and infectious diseases, oncology, neuroscience, and diabetes mellitus complications and kidney diseases. The company offers immunosuppressants, including Prograf, and Advagraf/ Graceptor/ ASTAGRAF XL; Vesicare and Betanis/Myrbetriq/BETMIGA for overactive bladder treatment; and Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia. It also provides Funguard/MYCAMINE, a candin antifungal agent; Protopic for atopic dermatitis; Eligard, XTANDI, and Gonax for prostate cancer treatment; Micardis, including Micombi and Micamlo BP for hypertension; Celecox, an anti-inflammatory agent; Symbicort for adult bronchial asthma and chronic obstructive pulmonary disease; Geninax for oral quinolone antibiotic; Bonoteo for osteoporosis; Cimzia for the treatment of adult patients with rheumatoid arthritis; and Suglat for type two diabetes treatments. In addition, the company offers Lipitor products for the treatment of hypercholesterolemia; Gaster for peptic ulcers and gastritis; Myslee for insomnia; Seroquel for schizophrenia; Regnite for restless legs syndrome; Kiklin for hyperphatemia treatments, as well as Lexiscan and Adenoscan, which are pharmacologic stress agents; and Tarceva for the treatment of lung and pancreatic cancers. Further, it provides Acofide for functional dyspepsia; Bisono Tape, a transdermal hypertension medication; diarrhea-predominant OD tablets; and dificlir for clostridium difficile infections. It has a strategic alliance with Amgen Inc. and ClearPath Development Company; and collaborative agreements with Immuno-Biological Laboratories Co., Ltd., Cytokinetics, Inc., Mitokyne, Inc., QIAGEN N.V., and Dana-Farber Cancer Institute. The company was founded in 1923 and is headquartered in Tokyo, Japan.

17,649 Employees
Last Reported Date: 06/18/14
Founded in 1923

astellas pharma inc (YPH) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥170.0M
Compensation as of Fiscal Year 2014.

astellas pharma inc (YPH) Key Developments

Astellas Pharma, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

Astellas Pharma, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

Osaka University and Astellas Sign Joint Research Agreement for Cell Therapies

Osaka University and Astellas Pharma Inc. have signed an agreement to establish a joint research chair, for developing fundamental technologies for next-generation cell therapies. Under the agreement, the joint research chair of Department of Translational Cell Therapy has been established within the Graduate School of Medicine/Faculty of Medicine, Osaka University and will be tasked with developing the new technology platforms required to advance practical use of cell therapies, which are expected to be the next-generation therapies. The department will operate a laboratory facility in the Bio Systems Building of the Graduate School of Frontier Biosciences. The primary research theme is development of technologies to make transfused/transplanted cells highly functional and to enhance their therapeutic effects through optimization of the sources of transfused/transplanted cells and the cell processing technologies, according to specific medical conditions. Other research themes will include analyses of immune responses induced by and the pharmacokinetics and safety of transfused cells for R&D, aimed at realizing practical utilization of allogeneic cell transplantation therapy. The joint research chair will be retained for a term of three years from January 2015. This joint research chair will address establishment of fundamental technologies for cell therapy research, early realization of clinical studies, and investigation of potential cell therapy candidates through collaborative research conducted by experts and researchers from Osaka University and Astellas in the fields of regenerative medicine and cell therapy. Joint research chair is a program for establishing a joint research chair at a university through collaboration between the university and one or more representatives of the relevant industry. This program is aimed at facilitating excellent research outcomes by focusing on sound objectives through collaborative research activities on common themes undertaken by researchers from the university and the sponsoring private company, which operate the program as equal partners.

Astellas Pharma, Inc., Q3 2015 Earnings Call, Feb 02, 2015

Astellas Pharma, Inc., Q3 2015 Earnings Call, Feb 02, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
YPH:GR €14.88 EUR -0.055

YPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $69.25 USD -0.17
Becton Dickinson and Co $148.36 USD +2.10
Boston Scientific Corp $16.79 USD +0.03
CSL Ltd A$92.00 AUD -0.18
Mylan NV $55.61 USD +0.17
View Industry Companies
 

Industry Analysis

YPH

Industry Average

Valuation YPH Industry Range
Price/Earnings 35.3x
Price/Sales 3.6x
Price/Book 3.2x
Price/Cash Flow 23.7x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC, please visit www.astellas.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.